1. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.
- Author
-
Zhi N, Mo Q, Yang S, Qin YX, Chen H, Wu ZG, Lan CH, Zhang J, and Li YL
- Subjects
- Administration, Oral, COVID-19 virology, Exudates and Transudates, Female, Humans, Inflammation drug therapy, Inflammation etiology, Lung pathology, Magnoliopsida, Middle Aged, Pulmonary Fibrosis etiology, SARS-CoV-2, COVID-19 complications, Drugs, Chinese Herbal therapeutic use, Lung drug effects, Medicine, Chinese Traditional, Phytotherapy, Pulmonary Fibrosis drug therapy
- Abstract
After one-month of oral treatment with traditional Chinese medicine decoction, without using other drugs, the lung inflammatory exudate, pulmonary fibrosis and quality of life of a 61-year-old female patient with corona virus disease 2019 (COVID-19) were significantly improved. No recurrence or deterioration of the patient's condition was found within seven weeks of treatment and follow-up, and no adverse events occurred, indicating that oral Chinese medicine decoction was able to improve the pulmonary inflammation and fibrosis in a patient recovering from COVID-19, but further research is still needed., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF